Discover our new website and eShop:

Our new site is easier to use, mobile-friendly, and personalized.

More about iPSCs on the new Lonza Bioscience website.


Building Bridges from Research to Therapy

Development of a Novel Progamming and Culture System for the Generation of Human iPSCs Under Defined cGMP Compliant Conditions

Speaker: Thomas Fellner, PhD, MBA
Director, Cell and Viral Therapies, Lonza

Register to Attend

Visit booth #301 to play Lonza Lotto for a chance to win an iPad® / iPod®*!


Thursday, 13 June 2013
Time: 12:30 – 1:00pm
Generation of hiPSCs in defined conditions is not only a prerequisite for the development of hiPSC-based therapies; it also has advantages in basic research applications.  Here we describe a novel reprogramming and culture system that combines a modified episomal plasmid-based technology with a newly developed medium, matrix and passaging solution. This cGMP-compliant system enables the efficient and robust generation of hiPSCs under defined conditions supporting the utilization of these cells for clinical applications.  

Learn More About Our Pluripotent Stem Cell Services

* Terms & Conditions apply